Leflunomide: A treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation

NDT Plus

Volumn 2, Issue 2, 2009, Pages 149-151

  Andrassy, Joachim ^a   Illner, Wilf Dieter ^a   Rentsch, Markus ^a   Jaeger, Gundula ^b   Jauch, Karl W ^a   Fischereder, Michael ^b  

^a Transplant Division   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

CMV; Ganciclovir; Leflunomide; Renal transplantation

Indexed keywords

BASILIXIMAB; CIDOFOVIR; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 77953938420     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp004     Document Type: Article

References (10)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751
2. Hibberd PL, Tolkoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients.Arandomized controlled trial. Ann Intern Med 1995; 123: 18-26
3. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12: 286-297
4. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovirresistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649
5. Ozaki KS, Camara NO, Nogueira E et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675-680
6. Drew WL, Miner RC, Marousek GI et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37: 124-127
7. West P, Schmiedeskamp M, Neeley H et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2008; 10: 129-132
8. Waldman WJ, Knight DA, Blinder L et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42: 412-418
9. John GT, Manivannan J, Chandy S et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37: 4303-4305
10. Levi ME, Mandava N, Chan LK et al. Treatment ofmultidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8: 38-43